Dr. Ellen Donnelly, PhD
CEO, Epigenetics Division, Juvenescence
This is a tremendous community, where we are all pushing the science forward. Our discussions and collaboration are invaluable. Our experience as drug developers becomes an asset we all can draw upon.
Dr. Ellen Donnelly, PhD is the Head of Epigenetics at Juvenescence and the CEO of Souvien Therapeutics.
At Juvenescence, Dr. Donnelly has found a group of like minded leaders and innovators.
“This is a tremendous community, where we are all pushing the science forward,” she says, “Our discussions and collaboration are invaluable. Our experience as drug developers becomes an asset we all can draw upon.”
Dr. Donnelly was the CEO of Modus Therapeutics, a Swedish biotech company that developed therapies to improve blood flow and oxygen transport, including sevuparin, a drug in development for sickle cell disease. Prior to Modus, Dr. Donnelly worked in R&D at Pfizer where she held leadership positions from the Head of Clinical Operations in Neuroscience and Pain, to Neuroscience research, project management and corporate strategy. Earlier in her career, she was a Therapeutic Area Lead at CombinatoRx, a biotech focused on the development of synergistic combination therapies. Dr. Donnelly also worked in management consulting with MEDACorp/Leerink Swann Strategic Advisors, a consulting group within the healthcare investment bank now called SVB Leerink.
Dr. Donnelly has a BS in genetics and an MFS in forensic molecular biology. She received her PhD from Yale University School of Medicine where she studied the modulation of voltage gated sodium channels in neurologic diseases.
Dr. Donnelly’s fitness pursuits connect to the outdoors and family: long hikes, bike rides, downhill skiing, paddle boarding and football with her husband and two children.